8-K: Achieve Life Sciences Stockholders Elect Directors, Ratify Auditor, But Reject Equity Plan Amendment at Annual Meeting

Achieve Life Sciences, Inc. announced the results of its Annual Meeting of Stockholders, where directors were elected and auditors ratified, but a proposal to increase shares for its non-employee director equity incentive plan was not approved.

Summary

• Achieve Life Sciences, Inc. held its Annual Meeting of Stockholders on June 4, 2025.
• Seven directors—Stuart Duty, Bridget Martell, Thomas B. King, Thomas Sellig, Richard Stewart, Nancy R. Phelan, and Kristen Slaoui—were elected to serve until the company's next annual meeting.
• The appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 26,459,791 votes for, 53,879 against, and 5,871 abstentions.
• An amendment to the company's 2023 Non-Employee Director Equity Incentive Plan, which sought to increase the number of shares available for issuance thereunder, was not approved by stockholders, with 7,982,633 votes against compared to 6,736,105 votes for, and 378,319 abstentions.

Sentiment

Score: 5

Explanation: The successful election of directors and ratification of auditors are positive for corporate stability. However, the rejection of the proposed amendment to the Non-Employee Director Equity Incentive Plan, which sought to increase shares for issuance, represents a setback for the company's compensation strategy for its non-employee directors, balancing the overall sentiment.

Positives

• All seven nominated directors were successfully elected, ensuring continuity in the Board of Directors.
• The appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025 was overwhelmingly ratified, indicating strong shareholder confidence in the company's financial oversight.

Negatives

• The proposed amendment to the 2023 Non-Employee Director Equity Incentive Plan, intended to increase available shares for issuance, was not approved by stockholders, with 'Against' votes exceeding 'For' votes by over 1.2 million (7,982,633 vs. 6,736,105).

Future Outlook

NA

Industry Context

This filing is primarily about corporate governance and does not provide specific industry context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the voting outcomes, particularly the rejection of the equity incentive plan amendment, which could affect future dilution or director compensation.
• Board of Directors: The elected directors will continue their roles. Non-employee directors may be impacted by the rejected equity incentive plan amendment, potentially affecting future compensation.
• Management: The rejection of the equity plan might require management to propose alternative compensation strategies for non-employee directors.

Next Steps

• The elected directors will serve until the company's next annual meeting or until their successors are duly elected and qualified.
• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Achieve Life Sciences, ACHV, SEC filing, 8-K, Annual Meeting, Stockholder Vote, Corporate Governance, Director Election, Auditor Ratification, Equity Incentive Plan, Shareholder Meeting, Biotechnology, Pharmaceuticals